Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Sarepta_Therapeutics
|
| gptkbp:acquisitionYear |
2019
|
| gptkbp:developedBy |
gene therapies for Limb-Girdle Muscular Dystrophy (LGMD)
|
| gptkbp:focusesOn |
gene therapy
rare muscle diseases |
| gptkbp:foundedIn |
2017
|
| gptkbp:headquartersLocation |
Ohio, United States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Myonexus Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:website |
https://www.myonexustx.com/
|
| gptkbp:bfsParent |
gptkb:Sarepta_Therapeutics
|
| gptkbp:bfsLayer |
7
|